US FDA Grants Approval For Zanidatamab Ziihera Bispecific Antibody For Biliary Tract Cancer
Global Bispecific Antibody Is Expected To Surpass US$ 40 Billion By 2029 Says Kuick ResearchDelhi, Nov. 25, 2024 (GLOBE ...
Pharmabiz3 天
US FDA approves Jazz Pharma’s Ziihera to treat adults with previously treated ...
Jazz Pharmaceuticals plc announced the US Food and Drug Administration (FDA) accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults ...
Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of ...
mskcc.org4 天
FDA Approves Zanidatamab for Biliary Tract Cancers With High HER2 Levels
Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved ...
Cancer Therapy Advisor3 天
Ziihera Approved for HER2+ Biliary Tract Cancer
The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive ...
FDA Approves Ziihera for HER2-Positive Biliary Tract Cancer
Ziihera is the first dual HER2-targeted bispecific antibody approved in the U.S. for HER2-positive biliary tract cancer ...
Medpage Today on MSN4 天
FDA Approves Zanidatamab for Biliary Tract Cancer
Patients in the open-label phase II trial had progressed on at least one gemcitabine-containing regimen and received ...
The American Journal of Managed Care4 天
FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer
Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.
US FDA declines full approval for Intercept's liver disease drug
The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...